Related Experiment Video
Updated: Jun 25, 2025
11:44
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
7.6K
LMNB1/CDKN1A Signaling Regulates the Cell Cycle and Promotes Hepatocellular Carcinoma Progression
Dute Gao1,2,3, Huahu Guo1,2,3, Zhaochen Liu1,2,3
1Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Current Cancer Drug Targets
|May 23, 2024
Summary
Lamin B1 (LMNB1) is overexpressed in hepatocellular carcinoma (HCC), promoting tumor growth and progression. Targeting LMNB1 may offer a new therapeutic strategy for HCC patients, correlating with immune cell infiltration.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Hepatocellular carcinoma (HCC) is a highly aggressive malignancy.
- Lamin B1 (LMNB1), a nuclear skeleton component, is increasingly recognized for its role in cancer.
- Previous studies indicate LMNB1 overexpression in tumors and association with patient prognosis, but its specific role in HCC remains unclear.
Purpose of the Study:
- To investigate the clinical significance of LMNB1 in HCC.
- To elucidate the molecular mechanisms underlying LMNB1's function in HCC progression.
- To explore the relationship between LMNB1 expression and immune cell infiltration in HCC.
Main Methods:
- Analysis of LMNB1 expression and clinical data from public databases.
- Validation of LMNB1 levels in HCC tissues using qRT-PCR and immunohistochemistry (IHC).
- In vitro and in vivo functional assays to assess LMNB1's impact on HCC cell proliferation.
- Gene enrichment analysis and ChIP assays to uncover molecular mechanisms.
- Correlation analysis between LMNB1 expression and immune cell infiltration markers.
Main Results:
- LMNB1 is significantly overexpressed in HCC tissues compared to normal tissues.
- Elevated LMNB1 expression correlates with advanced pathological stage and poorer patient prognosis.
- LMNB1 knockdown inhibits HCC cell proliferation both in vitro and in vivo.
- LMNB1 promotes HCC progression by regulating CDKN1A expression.
- A correlation exists between LMNB1 expression levels and the infiltration of specific immune cells in HCC.
Conclusions:
- Lamin B1 (LMNB1) is a significant driver of hepatocellular carcinoma (HCC) progression.
- LMNB1 serves as a potential prognostic biomarker and therapeutic target for HCC.
- LMNB1 expression is linked to the tumor immune microenvironment in HCC.
Related Concept Videos
01:07MAPK Signaling Cascades
5.4K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.4K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
02:39Positive Regulator Molecules
5.4K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.4K
02:15M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K